Nanjing Leads Biolabs Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-301.22	-362.25
Depreciation & Amortization	26.04	23.91
Loss (Gain) From Sale of Investments	-1.72	-6.24
Stock-Based Compensation	41.94	17.84
Other Operating Activities	45.81	115.96
Change in Inventory	-	2.04
Change in Accounts Payable	25.05	-1.55
Change in Unearned Revenue	84.22	-
Change in Other Net Operating Assets	-38.94	17.61
Operating Cash Flow	-118.82	-192.69
Capital Expenditures	-2.98	-11.73
Investment in Securities	-64.33	147.22
Investing Cash Flow	-67.3	135.49
Long-Term Debt Issued	274.98	61
Long-Term Debt Repaid	-86.34	-4.64
Net Debt Issued (Repaid)	188.64	56.37
Issuance of Common Stock	130.51	-
Other Financing Activities	-10.12	-6.87
Financing Cash Flow	309.02	49.49
Foreign Exchange Rate Adjustments	2.12	2.7
Net Cash Flow	125.02	-5
Free Cash Flow	-121.79	-204.41
Free Cash Flow Margin	-	-2305.84%
Free Cash Flow Per Share	-0.81	-1.41
Cash Interest Paid	5.19	6.87
Levered Free Cash Flow	-1,339	-
Unlevered Free Cash Flow	-1,336	-
Change in Working Capital	70.33	18.09

Source: S&P Global Market Intelligence. Standard template. Financial Sources.